SARM1 (Sterile Alpha and TIR Motif Containing 1) is a NAD+ hydrolase that plays a critical role in axonal degeneration.
SARM1 Inhibitor Therapy
SARM1 (Sterile Alpha and TIR Motif Containing 1) Inhibitor Therapy represents a novel neuroprotective approach targeting axonal degeneration in neurodegenerative diseases. SARM1 is a nicotinamide adenine dinucleotide (NAD+) hydrolase that plays a central role in the mechanistic pathway of axonal loss following injury or in chronic neurodegeneration. [@nmnat2022]
Mechanism of Action
SARM1 Biology
SARM1 is a bifunctional enzyme with both NAD+ cleavage activity and intrinsic TIR domain signaling capabilities. Under normal conditions, SARM1 exists in an auto-inhibited state. Upon activation by injury or disease-associated signals (particularly the loss of NMNAT2 - a key NAD+ biosynthetic enzyme), SARM1 undergoes a conformational change that triggers its enzymatic activity. [@sarm2024]
NAD+ Depletion
The primary pathogenic mechanism involves rapid and catastrophic depletion of cellular NAD+ levels through SARM1's intrinsic NAD+ hydrolase activity. This depletion occurs within hours of SARM1 activation and leads to: [@sarm2023a]
Energy failure due to NAD+ shortage for mitochondrial respiration
Axonal ATP depletion
Activation of PARP-mediated cell death pathways
Ultimately, axonal degeneration
NMNAT2 Protection
NMNAT2 (Nicotinamide mononucleotide adenylyltransferase 2) serves as the endogenous protector against SARM1-mediated axonal loss. NMNAT2 maintains axonal NAD+ levels and can directly inhibit SARM1 activation. The concept of SARM1 inhibitor therapy is to pharmacologically mimic or enhance this protective mechanism. [@alphasynuclein2022]
Preclinical Evidence
Alzheimer's Disease Models
SARM1 deletion or inhibition protects against [amyloid-beta](/proteins/amyloid-beta) induced axonal damage in mouse models [1]
Studies demonstrate preserved synaptic integrity in 5xFAD mice with SARM1 genetic deletion [3]
Parkinson's Disease Models
MPTP-induced dopaminergic neuron loss is attenuated in SARM1 knockout mice [4]
Axonal pathology in [alpha-synuclein](/proteins/alpha-synuclein) overexpression models is reduced with SARM1 inhibition [5]
Mitochondrial dysfunction-associated axonal degeneration is SARM1-dependent [6]
ALS Models
SARM1 inhibition preserves motor neuron axons in SOD1 G93A mouse models [7]
Axonal transport deficits are ameliorated by SARM1 genetic deletion [8]
Combination therapy with SOD1 antisense oligonucleotides shows enhanced benefit [9]
Clinical Trial Status
Currently, SARM1 inhibitors are in preclinical development with several pharmaceutical companies advancing candidates toward clinical trials: [@mitochondrial2023]
Challenges in Clinical Development
[Blood-brain barrier](/entities/blood-brain-barrier) penetration remains a key hurdle
Timing of intervention (early vs. established disease)
Biomarker development for target engagement
Safety profile considerations (SARM1's role in immune function)
Safety Profile Considerations
Potential Concerns
SARM1 is expressed in immune cells; systemic inhibition may affect immune response
Long-term NAD+ modulation may have unforeseen consequences
Species-specific differences in SARM1 biology
Preclinical Safety Data
SARM1 knockout mice are viable and fertile with mild metabolic phenotypes [10]
Acute inhibition shows acceptable toxicity profiles in rodent models